Back to top
more

Accuray (ARAY)

(Delayed Data from NSDQ)

$1.63 USD

1.63
511,514

-0.04 (-2.40%)

Updated May 17, 2024 04:00 PM ET

After-Market: $1.63 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (140 out of 249)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Accuray (ARAY) Reports Break-Even Earnings for Q3

Accuray (ARAY) delivered earnings and revenue surprises of -100.00% and 2.97%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights: Smith & Nephew, Intuitive Surgical, Stryker Corp, Accuray and Medtronic

The Zacks Analyst Blog Highlights: Smith & Nephew, Intuitive Surgical, Stryker Corp, Accuray and Medtronic

Sriparna Ghosal headshot

Coronavirus Ups the Game for Robotic Surgery: 3 Stocks on Radar

Let's keep a watch on the potentially strong three MedTech stocks, namely SYK, ARAY and MDT with respect to robotic-assisted surgery that showed promises during the pandemic.

Accuray (ARAY) Q2 Earnings and Revenues Surpass Estimates

Accuray (ARAY) registers growth in Service revenues during fiscal Q2.

Accuray (ARAY) Beats Q2 Earnings and Revenue Estimates

Accuray (ARAY) delivered earnings and revenue surprises of 600.00% and 4.96%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Accuray (ARAY) Releases Encouraging Breast Cancer Study Results

Accuray (ARAY) releases positive data from a prospective trial of 338 women with low-risk breast cancer.

Accuray (ARAY) Gets 510(k) Nod for ClearRT in TomoTherapy

Accuray (ARAY) new innovative imaging solution is designed to provide cost effective and exceptional diagnostic quality image.

Accuray (ARAY) Upgraded to Strong Buy: Here's What You Should Know

Accuray (ARAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Here's Why You Must Add Accuray (ARAY) to Your Portfolio Now

Investor confidence is high on Accuray (ARAY) stock, courtesy of its solid prospects.

Accuray (ARAY) Is Up 1.82% in One Week: What You Should Know

Does Accuray (ARAY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Accuray (ARAY) Inks Cancer Treatment Technology Delivery Deal

Accuray's (ARAY) new deal with DHL Supply Chain will help in the delivery of advanced cancer treatment technology.

Accuray (ARAY) Climbs 11.5% as Q1 Earnings Beat Estimates

Accuray (ARAY) registered growth in Service revenues in Q1.

Accuray (ARAY) Reports Break-Even Earnings for Q1

Accuray (ARAY) delivered earnings and revenue surprises of 100.00% and 10.82%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Accuray (ARAY) Report Negative Earnings Next Week? What You Should Know

Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Retain Accuray (ARAY) Stock for Now

Investors' confidence is high in the Accuray (ARAY) stock, thanks to its solid prospects.

The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific, DaVita, Accuray and Cardinal Health

The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific, DaVita, Accuray and Cardinal Health

Sriparna Ghosal headshot

3 Best MedTech Value Stocks to Buy Ahead of Q3 Earnings

These three MedTech stocks are expected to grow post their Q3 earnings release.

Idexx (IDXX) Hits 52-Week High, Can the Run Continue?

Idexx (IDXX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Trina Mukherjee headshot

Robot-Assisted Surgery Gains Momentum Amid Coronavirus

Let's keep a watch on potentially strong three MedTech stocks with respect to robotic-assisted surgery that have shown promise during the pandemic.

Accuray's Radixact With Synchrony Used in Japan Hospitals

The integration of Synchrony to Accuray's (ARAY) Radixact System will ensure that the hospital teams can efficiently deliver precise radiation doses to tumors.

Accuray (ARAY) Down 16.5% Since Last Earnings Report: Can It Rebound?

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Accuray (ARAY) Reports Loss in Q4, Revenues Miss Estimates

Accuray (ARAY) registered decline in Product and Service revenues in Q4

Accuray (ARAY) Earnings Expected to Grow: Should You Buy?

Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sriparna Ghosal headshot

3 Large-Cap MedTech Stocks to Buy on Northbound Market Trend

Backed by an upward trend of share prices and projections of robust earnings growth rates, there are a few MedTech stocks which are ideal for long-term bet.

Sriparna Ghosal headshot

Coronavirus Spurs Growth for 3 Robotics-Assisted Surgery Stocks

In the face of the pandemic, the robotics-assisted surgery space continues to thrive on a slew of positive developments.